26 April 2018 
EMA/CHMP/254059/2018 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Tagrisso 
osimertinib 
On 26 April 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Tagrisso. The marketing authorisation holder for this medicinal product is AstraZeneca AB. 
The CHMP adopted an extension to the existing indication as follows2: 
“Tagrisso as monotherapy is indicated for: 
• 
• 
the first-line treatment of adult patients with locally advanced or metastatic non-small 
cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) 
mutations. 
the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive 
NSCLC.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
